These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 19275700)

  • 1. Drug targets in herpes simplex and Epstein Barr Virus infections.
    Billaud G; Thouvenot D; Morfin F
    Infect Disord Drug Targets; 2009 Apr; 9(2):117-25. PubMed ID: 19275700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel targets for the development of anti-herpes compounds.
    Greco A; Diaz JJ; Thouvenot D; Morfin F
    Infect Disord Drug Targets; 2007 Mar; 7(1):11-8. PubMed ID: 17346207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perspectives on interactions of acyclovir with Epstein-Barr and other herpes viruses.
    Pagano JS; Datta AK
    Am J Med; 1982 Jul; 73(1A):18-26. PubMed ID: 6285710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential effects of acyclovir and 9-(1,3-dihydroxy-2-propoxymethyl)guanine on herpes simplex virus and Epstein-Barr virus in a dually infected human lymphoblastoid cell line.
    van der Horst CM; Lin JC; Raab-Traub N; Smith MC; Pagano JS
    J Virol; 1987 Feb; 61(2):607-10. PubMed ID: 3027389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tenofovir prodrugs potently inhibit Epstein-Barr virus lytic DNA replication by targeting the viral DNA polymerase.
    Drosu NC; Edelman ER; Housman DE
    Proc Natl Acad Sci U S A; 2020 Jun; 117(22):12368-12374. PubMed ID: 32409608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Prevention and therapy of herpesvirus infections].
    Abb J
    Zentralbl Bakteriol Mikrobiol Hyg B; 1985 Feb; 180(2-3):107-20. PubMed ID: 2986378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging therapies for herpes viral infections (types 1 - 8).
    Chakrabarty A; Pang KR; Wu JJ; Narvaez J; Rauser M; Huang DB; Beutner KR; Tyring SK
    Expert Opin Emerg Drugs; 2004 Nov; 9(2):237-56. PubMed ID: 15571482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new promising candidate to overcome drug resistant herpes simplex virus infections.
    Zinser E; Krawczyk A; Mühl-Zürbes P; Aufderhorst U; Draßner C; Stich L; Zaja M; Strobl S; Steinkasserer A; Heilingloh CS
    Antiviral Res; 2018 Jan; 149():202-210. PubMed ID: 29155164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brincidofovir clearance of acyclovir-resistant herpes simplex virus-1 and adenovirus infection after stem cell transplantation.
    Voigt S; Hofmann J; Edelmann A; Sauerbrei A; Kühl JS
    Transpl Infect Dis; 2016 Oct; 18(5):791-794. PubMed ID: 27482652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel Therapeutics for Epstein⁻Barr Virus.
    Andrei G; Trompet E; Snoeck R
    Molecules; 2019 Mar; 24(5):. PubMed ID: 30871092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epstein-Barr virus infections: prospects for treatment.
    Gershburg E; Pagano JS
    J Antimicrob Chemother; 2005 Aug; 56(2):277-81. PubMed ID: 16006448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stromal keratitis and anterior uveitis due to herpes simplex virus-2 in a young child.
    Inoda S; Wakakura M; Hirata J; Nakazato N; Toyo-Oka Y
    Jpn J Ophthalmol; 2001; 45(6):618-21. PubMed ID: 11754904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [New targets for new anti-herpes drugs].
    Morfin F; Frobert E; Calle A; Thouvenot D; Diaz JJ; Greco A
    Virologie (Montrouge); 2007 Dec; 11(6):423-432. PubMed ID: 36131465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiviral therapy of herpes simplex.
    Snoeck R
    Int J Antimicrob Agents; 2000 Oct; 16(2):157-9. PubMed ID: 11053800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 5-(1-Substituted) alkyl pyrimidine nucleosides as antiviral (herpes) agents.
    Kumar R
    Curr Med Chem; 2004 Oct; 11(20):2749-66. PubMed ID: 15544474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current and future therapies for herpes simplex virus infections: mechanism of action and drug resistance.
    James SH; Prichard MN
    Curr Opin Virol; 2014 Oct; 8():54-61. PubMed ID: 25036916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiviral resistance in herpes simplex virus and varicella-zoster virus infections: diagnosis and management.
    Piret J; Boivin G
    Curr Opin Infect Dis; 2016 Dec; 29(6):654-662. PubMed ID: 27306564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug-resistant herpes simplex virus in vitro and after acyclovir treatment in an immunocompromised patient.
    Schnipper LE; Crumpacker CS; Marlowe SI; Kowalsky P; Hershey BJ; Levin MJ
    Am J Med; 1982 Jul; 73(1A):387-92. PubMed ID: 6285729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel agents and strategies to treat herpes simplex virus infections.
    Kleymann G
    Expert Opin Investig Drugs; 2003 Feb; 12(2):165-83. PubMed ID: 12556212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beta interferon plus gamma interferon efficiently reduces acyclovir-resistant herpes simplex virus infection in mice in a T-cell-independent manner.
    Huang WY; Su YH; Yao HW; Ling P; Tung YY; Chen SH; Wang X; Chen SH
    J Gen Virol; 2010 Mar; 91(Pt 3):591-8. PubMed ID: 19906941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.